[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f3pftnc73qwmur":3,"organisation-30e76681-639e-4fbd-b386-b506ba4fee17":5,"organisation-articles-30e76681-639e-4fbd-b386-b506ba4fee17":11},{"hasError":4,"data":5},false,{"id":6,"title":7,"color":8,"path":9,"logoUrl":10},"30e76681-639e-4fbd-b386-b506ba4fee17","Matisse Pharmaceuticals B.V.","","matissepharmaceuticals","https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Flogos\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002F6980a729-3571-4cff-a3ed-51c20c6e1da3.jpg",[12,24,33,43,50,57,66,75,83],{"id":13,"title":14,"pubDate":15,"logoUrl":16,"thirdParty":4,"imageUrls":17,"orgId":6,"branches":19,"description":23},"bd9fde26-b811-4628-8b39-f5666e6ef8a4","Matisse Pharmaceuticals en EpiDisease ontvangen EU-financiering voor eHISTOCURE-project","2025-06-26T10:00:00.031+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002F6980a729-3571-4cff-a3ed-51c20c6e1da3.jpg",[18],"https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002Fbd9fde26-b811-4628-8b39-f5666e6ef8a4\u002F20250626ENMatissereceivesEurostarsgrantLI.pdf",[20],{"id":21,"title":22},"29100","Zorg","Geleen, 26 juni, 2025. Matisse Pharmaceuticals B.V., een bedrijf dat momenteel een geneesmiddel in de klinische ontwikkelingsfase heeft voor de behandeling van ",{"id":25,"title":26,"pubDate":27,"logoUrl":16,"thirdParty":4,"imageUrls":28,"orgId":6,"branches":30,"description":32},"7440985c-cb18-4aa7-a0fb-0e4b98c52849","Matisse krijgt goedkeuring van BfArM voor studie naar een langdurig infuus met M6229","2024-10-24T10:00:00.044+02:00",[29],"https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002F7440985c-cb18-4aa7-a0fb-0e4b98c52849\u002F20241024FinalPressReleaseMatisseHVstudyENL.pdf",[31],{"id":21,"title":22},"Geleen, 24 oktober, 2024 Matisse Pharmaceuticals B.V., een bedrijf dat een geneesmiddel ontwikkelt voor de behandeling van sepsis, heeft vandaag aangekondigd da",{"id":34,"title":35,"pubDate":36,"logoUrl":16,"thirdParty":4,"imageUrls":37,"orgId":6,"branches":40,"description":42},"8d7ed437-110f-4571-919b-791466574383","Matisse Pharmaceuticals benoemt prof. Carolyn Calfee tot lid van de Wetenschappelijke Raad","2024-10-22T10:00:00.041+02:00",[38,39],"https:\u002F\u002Flh3.googleusercontent.com\u002Fe8cWlW3xFNCB3OT6TI_oegCqJYaz-knhgdDnFcaS3J8_G4VKMhOxz4OAYVw7BeL6p3JHy6GTMTWfgPllhOscUSKO2s48N4gykxo","https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002F8d7ed437-110f-4571-919b-791466574383\u002F20241022FinalPressReleaseMatisseappointsCarolynCalfeetoScientificBoardENL.pdf",[41],{"id":21,"title":22},"Geleen, 22 oktober, 2024 Matisse Pharmaceuticals B.V., een bedrijf dat een geneesmiddel ontwikkelt voor de behandeling van sepsis, kondigt de benoeming aan van ",{"id":44,"title":45,"pubDate":46,"logoUrl":16,"thirdParty":4,"orgId":6,"branches":47,"description":49},"57d8e5c0-87f5-43cd-8d96-f696a0e6037a","Matisse Pharmaceuticals behaalt primaire doelstellingen in studie bij sepsispatiënten","2024-01-30T11:00:00.163+01:00",[48],{"id":21,"title":22},"Matisse Pharmaceuticals B.V., een bedrijf dat een geneesmiddel ontwikkelt voor de behandeling van sepsis, heeft vandaag de eerste resultaten bekendgemaakt van d",{"id":51,"title":52,"pubDate":53,"logoUrl":16,"thirdParty":4,"orgId":6,"branches":54,"description":56},"b556e2bd-956d-4820-9151-eee34f8aa152","Matisse Pharmaceuticals closes EUR 3.6 million financing round","2024-01-04T11:30:00.029+01:00",[55],{"id":21,"title":22},"Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, is pleased to announce that has finalized a s",{"id":58,"title":59,"pubDate":60,"logoUrl":16,"thirdParty":4,"imageUrls":61,"orgId":6,"branches":63,"description":65},"cd533176-c13a-4247-b065-8093bec622dd","Matisse Pharmaceuticals appoints Marcel Jacobs as CEO","2024-01-02T12:49:51.604+01:00",[62],"https:\u002F\u002Flh3.googleusercontent.com\u002FeTjYX2Y1ZAevJLJhDTh2vD0RbvwHuJfsPNhWP08ztmrT0NEm_MzlO_S_ltH618SimQr8q5tEbea4lI56zLeqplRt0JrPI4vJ",[64],{"id":21,"title":22},"Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, is pleased to announce that it has appointed ",{"id":67,"title":68,"pubDate":69,"logoUrl":16,"thirdParty":4,"orgId":6,"branches":70,"description":74},"45066e9f-55f0-4390-9b37-870ed6b58eb7","Matisse Pharmaceuticals strengthens Scientific Board with Profs. J. Marshall & M. Singer","2023-05-23T13:04:13.087+02:00",[71],{"id":72,"title":73},"26100","Economie en geld","Matisse Pharmaceuticals strengthens Scientific Advisory Board with Prof. John Marshall and Prof. Mervyn Singer Matisse Pharmaceuticals B.V., a clinical stage co",{"id":76,"title":68,"pubDate":77,"logoUrl":16,"thirdParty":4,"imageUrls":78,"orgId":6,"branches":81,"description":74},"ae0d05fa-d472-485f-87ad-5d5a8e824f97","2023-05-23T12:30:00.030+02:00",[79,80],"https:\u002F\u002Flh3.googleusercontent.com\u002FvE7grMlX9atlG7-hcLFa3hhRjRaW70gCvOv0X_Oi2fSTPpd1IuUVVC2Y5_0rKYV0Sp5Y4_m-ADSTp7iISI9j7P28evjoZRDauw","https:\u002F\u002Flh3.googleusercontent.com\u002FlFhNxWRNBVYdAdv-xFsAfKBdnYPLg1PyEr0mIgJIi7riksRe1oYJGmefdWHhkcPS79C7xQJXb1srw0TJL7TvUUwMe7QxjPQj-w",[82],{"id":72,"title":73},{"id":84,"title":85,"pubDate":86,"logoUrl":16,"thirdParty":4,"imageUrls":87,"orgId":6,"branches":89,"description":93},"fc7647f6-7f12-4e33-a125-0ce4833eee0a","Matisse Pharmaceuticals krijgt akkoord voor dosisverhoging M6229 in septische patiënten","2022-09-07T17:05:47.063+02:00",[88],"https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002Ffc7647f6-7f12-4e33-a125-0ce4833eee0a\u002FPersberichtMatissePharmaceuticalskrijgtakkoordvoorverhogendosisinsepsispatienten.pdf",[90],{"id":91,"title":92},"38100","Algemeen nieuws","Matisse Pharmaceuticals staat op het punt een derde dosisniveau te starten in een Fase I\u002FIIa studie met zijn lead compound M6229 bij septische patiënten. Geleen"]